Autopsy report · NCT02377336

GS-6615 in Adults With Chronic Stable Angina and Coronary Artery Disease

“Anticipated recruitment challenges”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Gilead Sciences

Sponsor type

Industry

Conditions

Ischemic Heart Disease

Interventions

GS-6615; Placebo

Participants

0

Trials that died the same way

• Control of COVID-19 Outbreaks in Long Term Care
  “Recruitment challenges” (94% match in meaning)
• Effects of Evening Dose of Immediate Release Methylphenidate on Sleep in Children With ADHD
  “challenge in recruitment” (90% match in meaning)
• Ospemifene vs. Conjugated Estrogens in the Treatment of Postmenopausal Sexual Dysfunction
  “Obstacles with recruitment” (86% match in meaning)
• Prospective Assessment of Impact of Personalized Dosing of Low-dose Human Chorionic Gonadotropin (hCG) on in Vitro Fertilization (IVF) Outcomes
  “recruitment issues” (84% match in meaning)
• Trial Study of an Exercise Program for Youth With Persistent Symptoms After Concussion
  “feasibility; challenges with recruitment” (84% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.